
- Volume 0 0
MYLAN BARRED FROM SELLING GENERIC TOPAMAX
A federal judge in NewJersey issued an injunctionpermanently barringMylan Pharmaceuticalsfrom selling generic topiramatetablets and capsulesin the United Statesbefore September 26,2008, the expiration dateof the patent for TOPAMAX(topiramate) heldby Ortho-McNeil NeurologicsInc. Mylan hadchallenged the validity ofthat patent and filed anabbreviated new drugapplication to market ageneric version of theepilepsy drug. The brandedmanufacturer counteredwith a patentinfringement complaintagainst Mylan and obtaineda preliminary injunctionagainst the genericfirm last fall.
Articles in this issue
over 18 years ago
can you READ these Rxs?over 18 years ago
compounding HOTLINEover 18 years ago
Pseudoephedrine Logs Need Constant Tendingover 18 years ago
Another Federal Court Rejects a Drug Importation Planover 18 years ago
Home Infusion Therapy Gets Patients Out of the Hospitalover 18 years ago
RESPy AWARD: Teamwork Is the Thread That Bindsover 18 years ago
Child-resistant Does Not Mean Childproofover 18 years ago
ccpa SPEAKS OUT: CCPA Works to Improve Medicare Part Dover 18 years ago
Genetic Testing: Remarkable Resource or Invasion of Privacy?over 18 years ago
case STUDIESNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.













































































































































































































